|
1
|
Kanis JA: Diagnosis of osteoporosis and
assessment of fracture risk. Lancet. 359:1929–1936. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hohenhaus MH, McGarry KA and Col NF:
Hormone therapy for the prevention of bone loss in menopausal women
with osteopenia: Is it a viable option? Drugs. 67:2311–2321. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Levine JP: Effective strategies to
identify postmenopausal women at risk for osteoporosis. Geriatrics.
62:22–30. 2007.PubMed/NCBI
|
|
4
|
Krane SM and Inada M: Matrix
metalloproteinases and bone. Bone. 43:7–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mott JD and Werb Z: Regulation of matrix
biology by matrix metalloproteinases. Curr Opin Cell Biol.
16:558–564. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Andersen TL, del Carmen Ovejero M,
Kirkegaard T, Lenhard T, Foged NT and Delaissé JM: A scrutiny of
matrix metalloproteinases in osteoclasts: Evidence for
heterogeneity and for the presence of MMPs synthesized by other
cell. Bone. 35:1107–1119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tezuka K, Nemoto K, Tezuka Y, Sato T,
Ikeda Y, Kobori M, Kawashima H, Eguchi H, Hakeda Y and Kumegawa M:
Identification of matrix metalloproteinase-9 in rabbit osteoclasts.
J Biol Chem. 269:15006–15009. 1994.PubMed/NCBI
|
|
8
|
Inoue K, Mikuni-Takagaki Y, Oikawa K, Itoh
T, Inada M, Noguchi T, Park JS, Onodera T, Krane SM, Noda M and
Itohara S: A crucial role for matrix metalloproteinase 2 in
osteocytic canalicular formation and bone metabolism. J Biol Chem.
281:33814–33824. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Engsig MT, Chen QJ, Vu TH, Pedersen AC,
Therkidsen B, Lund LR, Henriksen K, Lenhard T, Foged NT, Werb Z and
Delaissé JM: Matrix metalloproteinase 9 and vascular endothelial
growth factor are essential for osteoclast recruitment into
developing long bones. J Cell Biol. 151:879–889. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Varghese S and Canalis E: Alendronate
stimulates collagenase 3 expression in osteoblasts by
posttranscriptional mechanisms. J Bone Miner Res. 15:2345–235l.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun B, Sun J, Han X, Liu H, Li J, Du J,
Feng W, Liu B, Cui J, Guo J, et al: Immunolocalization of MMP 2, 9
and 13 in prednisolone induced osteoporosis in mice. Histol
Histopathol. 31:647–656. 2016.PubMed/NCBI
|
|
12
|
Tang SY, Herber RP, Ho SP and Alliston T:
Matrix metalloproteinase-13 is required for osteocytic perilacunar
remodeling and maintains bone fracture resistance. J Bone Miner
Res. 27:1936–1950. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Egermann M, Goldhahn J and Schneider E:
Animal models for fracture treatment inosteoporosis. Osteoporosis
Int. 16 Suppl 2:S129–S138. 2005. View Article : Google Scholar
|
|
15
|
Samanna V, Ma T, Mak TW, Rogers M and
Chellaiah MA: Actin polymerization modulates CD44 surface
expression, MMP-9 activation, and osteoclast function. J Cell
Physiol. 213:710–720. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang P and Zhong M: Effects of
17beta-estradiol and progesterone on the expression of matrix
metalloproteinases and tissue inhibitors of metalloproteinases in
rat osteoblasts. Di Yi Jun Yi Da Xue Xue Bao. 21:929–931.
2001.PubMed/NCBI
|
|
17
|
Bachmeier BE, Iancu CM, Jochum M and
Nerlich AG: Matrix metalloproteinases in cancer: Comparison of
known and novel aspects of their inhibition as a therapeutic
approach. Expe Rev Anticancer Ther. 5:149–163. 2005. View Article : Google Scholar
|
|
18
|
Martignetti JA, Aqeel AA, Sewairi WA,
Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O,
Harris J, et al: Mutation of the matrix metalloproteinase 2 gene
(MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat
Genet. 28:261–265. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nyman JS, Lynch CC, Perrien DS, Thiolloy
S, O'Quinn EC, Patil CA, Bi X, Pharr GM, Mahadevan-Jansen A and
Mundy GR: Differential effects between the loss of MMP-2 and MMP-9
on structural and tissue-level properties of bone. J Bone Miner
Res. 26:1252–1260. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao H, Cai G, Du J, Xia Z, Wang L and Zhu
T: Expression of matrix metalloproteinase-9 mRNA in osteoporotic
bone tissues. J Tongji Med Univ. 17:28–31. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Filanti C, Dickson GR, Di Martino D, Ulivi
V, Sanguineti C, Romano P, Palermo C and Manduca P: The expression
of metalloproteinase-2, −9, and −14 and of tissue inhibitors-1 and
−2 is developmentally modulated during osteogenesis in vitro, the
mature osteoblastic phenotype expressing metalloproteinase-14. J
Bone Miner Res. 15:2154–2168. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jemtlan R, Holden M, Reppe S, Olstad OK,
Reinholt FP, Gautvik VT, Refvem H, Frigessi A, Houston B and
Gautvik KM: Molecular disease map of bone characterizing the
postmenopausal osteoporosis phenotype. J Bone Miner Res.
26:1793–1801. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pivetta E, Scapolan M, Pecolo M,
Wassermann B, Abu-Rumeileh I, Balestreri L, Borsatti E, Tripodo C,
Colombatti A and Spessotto P: MMP-13 stimulates osteoclast
differentiation and activation in tumour breast bone metastases.
Breast Cancer Res. 13:R1052011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Liao EY, Dai RC, Wei QY and Luo XH:
Effects of 17 beta-estradiol on the expression of interstitial
collagenases-8 and −13 (MMP-8 and MMP-13) and tissue inhibitor of
metalloproteinase-1 (TIMP-1) in ovariectomized rat osteoblastic
cells. J Mol Histol. 35:723–731. 2004. View Article : Google Scholar : PubMed/NCBI
|
